Cereno Scientific AB (publ) (4A1.F)

0,3710 +0,0056 (+1,53%) In data: 09:16AM CEST. Mercato aperto.

Cereno Scientific AB (publ)

BioVentureHub
Pepparedsleden 1 Mölndal
Gothenburg 431 83
Sweden
46 768 66 77 87
https://www.cerenoscientific.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 5

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Sten R. Sorensen	CEO & Director	7,35M	N/D	1959
Mr. Jonas Faijerson Saljo	Chief Intellectual Property Officer	893k	N/D	1977
Ms. Eva Jagenheim	Chief Financial Officer	N/D	N/D	1966
Dr. Bjorn Dahlof FACC, FESC, M.D., Ph.D.	Chief Scientific Officer	96k	N/D	1953
Henrik Westdahl	Director of Communications & IR	N/D	N/D	1985
Ms. Tove Bergenholt	Director of Communications & IR (currently on parental leave)	N/D	N/D	1988
Mr. Fredrik Frick	Head of Clinical Operations	N/D	N/D	1973
Mr. Nicholas Oakes	Head of Preclinical Development	N/D	N/D	1961
Dr. Rahul Agrawal M.D.	Chief Medical Officer & Head of R&D	N/D	N/D	1965

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System, as well as collaboration with the Pulmonary and Vascular Research Institute (PVRI). Cereno Scientific AB (publ) was founded in 2012 and is headquartered in Gothenburg, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Cereno Scientific AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.